Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Flu vaccine showdown: which type works best?

NCT ID NCT05479370

Vaccine Sponsor: Tan Tock Seng Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared three different flu vaccines: one made using eggs, one using cells, and one using a lab-made protein. The goal was to see which vaccine triggers the strongest antibody response, especially against a tricky flu strain called H3N2. 366 adults who hadn't had a flu shot in the last 6 months took part, and their immune responses were tracked over nearly a year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

366 people

The number who actually took part.

Started

Sep 2022

Finished

Feb 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 49 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to provide informed consent * Willing and able to provide 4 blood samples at D0, 14, 150 and 330 post-vaccination * Has not received influenza vaccine for at least 6 months * Willing to provide current mobile phone number for SMS reminders Exclusion Criteria: * Known contraindication(s) for QIV (e.g. hypersensitivity to vaccine component (including eggs)). * Recently (last 7 days) or currently ill or has a fever above 38 degrees celsius * Cannot recall if they were vaccinated against influenza during more or less than two of the preceding five years. Vaccinated during two of the preceding five years. * Hypogammaglobulinaemia on immunoglobulin replacement * Undergoing immunosuppressive therapies including corticosteroids

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Influenza vaccination are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

influenza

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Influenza vaccination

Contacts and locations

Locations

  • National Centre for Infectious Diseases (NCID)

    Singapore, Singapore, 308442, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.